Long-term outcomes following systemic treatment of acute GVHD.P values express the difference between the itacitinib (Ita) and the systemic corticosteroid (SCS) groups. The Gray test was used to compare cumulative incidences, and the log-rank test was used to compare survival between groups. (A) Relapse: P = .64. (B) cGVHD: P = .33. (C) NRM: P = .21. (D) Overall survival (OS): P = .11.